Pfizer (PFE) Raw Materials (2009 - 2019)

Pfizer (PFE) has reported Raw Materials for 11 consecutive years, with $560.0 million the latest figure, recorded in Q1 2019.

• On a quarterly basis, Raw Materials fell 32.12% year-over-year to $560.0 million in Q1 2019; TTM through Mar 2019 was $560.0 million, a 32.12% decrease from a year earlier, with the FY2018 full-year figure at $546.0 million, down 30.71% from the prior year.
• Raw Materials was $560.0 million for Q1 2019 at Pfizer, up from $546.0 million in the prior quarter.
• Over five years, Raw Materials peaked at $950.0 million in Q3 2016 and troughed at $475.0 million in Q1 2015.
• A 5-year average of $741.2 million and a median of $793.0 million in 2016 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials jumped 84.82% in 2016 and sank 32.12% in 2019, its largest moves.
• Over 5 years, Raw Materials stood at $867.0 million in 2015, then retreated by 8.54% to $793.0 million in 2016, then dropped by 0.63% to $788.0 million in 2017, then plunged by 30.71% to $546.0 million in 2018, then gained by 2.56% to $560.0 million in 2019.
• The last three Raw Materials figures came in at $560.0 million (Q1 2019), $546.0 million (Q4 2018), and $839.0 million (Q3 2018), per Business Quant data.